Abstract:BACKGROUND:Both pharmacologic and genetic approaches have been used to study the involvement of the muscarinic acetylcholine system in the regulation of chronic pain. Previous studies suggest that the M2 and M4 subtypes of muscarinic acetylcholine receptors (mAChRs) are important targets for the development of chronic pain. (5R,6R)6-(3-Propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1] octane (PTAC) has agonist effects on muscarinic M2 and M4 receptors and antagonist effects on muscarinic M1, M3, and M5 receptors. However, its analgesic effects have been less studied. METHODS:Male C57B L/6 mice were anesthetized, and left common peroneal nerve (CPN) ligation was performed to induce neuropathic pain. Before and after the application of PTAC systemically or specifically to the anterior cingulate cortex (ACC), the withdrawal thresholds to mechanical stimulation and static weight balance were measured, and the effects of PTAC on the conditioned place preference (CPP) were further evaluated. Western blotting was used to examine the expression of M1 and M2 in the striatum, ACC, and ventral tegmental area. RESULTS:The application of PTAC ([i.p.] intraperitoneal injection) increased the paw withdraw threshold in both the early (0.05 mg/kg, mean difference [95% confidence interval, CI]: 0.19 [0.05-0.32]; 0.10 mg/kg: mean difference [95% CI]: 0.34 [0.22-0.46]) and the late phases (0.05 mg/kg: mean difference [95% CI]: 0.45 [0.39-0.50]; 0.1 mg/kg: mean difference [95% CI]: 0.44 [0.37-0.51]) after nerve injury and rebalanced the weight distribution on the hind paws of mice (L/R ratio: before, 0.56 ± 0.03. 0.05 mg/kg, 1.00 ± 0.04, 0.10 mg/kg, 0.99 ± 0.03); however, it failed to induce place preference in the CPP (0.05 mg/kg, 2-way analysis of variance, P > .05; 0.2 mg/kg, 2-way analysis of variance, P > .05,). At the same doses, the analgesic effects at D3-5 lasted longer than the effects at D14-16. This may be due to the down-regulation of the M2 and M1 in tested brain regions. CONCLUSIONS:These observations suggested that PTAC has analgesic effects on the neuropathic pain induced by nerve injury.

Neuropeptide S Produces Antinociceptive Effects at the Supraspinal Level in Mice

Neuropeptide S inhibits the acquisition and the expression of conditioned place preference to morphine in mice.

S1PR2 Deficiency Enhances Neuropathic Pain Induced by Partial Sciatic Nerve Ligation

A Synthetic Peptide Exerts Nontolerance-Forming Antihyperalgesic and Antidepressant Effects in Mice

Neuropeptide S Facilitates Mice Olfactory Function Through Activation Of Cognate Receptor-Expressing Neurons In The Olfactory Cortex

The Ventromedial Hypothalamic Nucleus Plays an Important Role in Anxiolytic-Like Effect of Neuropeptide S

Neuropeptide S Attenuates the Alarm Pheromone-Evoked Defensive and Risk Assessment Behaviors Through Activation of Cognate Receptor-Expressing Neurons in the Posterior Medial Amygdala

Effect of Intrathecal Injection of Neuropeptide S and Gabapentin on Pain and Anxiety Behavior in Rats with Neuropathic Pain

Central Neuropeptide S Inhibits Distal Colonic Transit Through Activation of Central Neuropeptide S Receptor in Mice

The Analgesic Effects of (5R,6R)6-(3-Propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1] Octane on a Mouse Model of Neuropathic Pain.

Effects of Nociceptin (13–17) in Pain Modulation at Supraspinal Level in Mice

Central administration of neuropeptide FF and related peptides attenuate systemic morphine analgesia in mice.

Effects of Neuropeptide Ff System on Cb1 and Cb2 Receptors Mediated Antinociception in Mice

MCRT, a Multifunctional Ligand of Opioid and Neuropeptide FF Receptors, Attenuates Neuropathic Pain in Spared Nerve Injury Model

Neuropeptide S Induces Acute Anxiolysis by Phospholipase C-Dependent Signaling within the Medial Amygdala

Spexin/NPQ Induces FBJ Osteosarcoma Oncogene (fos) and Produces Antinociceptive Effect Against Inflammatory Pain in the Mouse Model

BN-9, a Chimeric Peptide with Mixed Opioid and Neuropeptide FF Receptor Agonistic Properties, Produces Nontolerance-Forming Antinociception in Mice.

Systemic Administration of the Bifunctional Opioid/neuropeptide FF Receptors Agonist BN-9 Produced Peripheral Antinociception in Preclinical Mouse Models of Pain

Effects of Nocistatin and Nocistatin (10-17) on Nociceptin in Antagonizing Endomorphin-1 and Endomorphin-2 Analgesia in Mice

Supraspinal Hyperalgesia and Spinal Analgesia by [Phe1ψ(ch2-Nh)gly2]nociceptin-(1–13)-nh2 in Rat

Neuropeptide S facilitates spatial memory and mitigates spatial memory impairment induced by N-methyl-D-aspartate receptor antagonist in mice.